Literature DB >> 30192094

Management of common adverse effects of antipsychotic medications.

T Scott Stroup1, Neil Gray2.   

Abstract

The benefits of antipsychotic medications are sometimes obscured by their adverse effects. These effects range from relatively minor tolerability issues (e.g., mild sedation or dry mouth) to very unpleasant (e.g., constipation, akathisia, sexual dysfunction) to painful (e.g., acute dystonias) to disfiguring (e.g., weight gain, tardive dyskinesia) to life-threatening (e.g., myocarditis, agranulocytosis). Importantly, adverse effect profiles are specific to each antipsychotic medication and do not neatly fit into first- and second-generation classifications. This paper reviews management strategies for the most frequent side effects and identifies common principles intended to optimize net antipsychotic benefits. Only use antipsychotics if the indication is clear; only continue antipsychotics if a benefit is discernible. If an antipsychotic is providing substantial benefit, and the adverse effect is not life-threatening, then the first management choice is to lower the dose or adjust the dosing schedule. The next option is to change the antipsychotic; this is often reasonable unless the risk of relapse is high. In some instances, behavioral interventions can be tried. Finally, concomitant medications, though generally not desirable, are necessary in many instances and can provide considerable relief. Among concomitant medication strategies, anticholinergic medications for dystonias and parkinsonism are often effective; beta-blockers and anticholinergic medications are useful for akathisia; and metformin may lead to slight to moderate weight loss. Anticholinergic drops applied sublingually reduce sialorrhea. Usual medications are effective for constipation or dyslipidemias. The clinical utility of recently approved treatments for tardive dyskinesia, valbenazine and deutetrabenazine, is unclear.
© 2018 World Psychiatric Association.

Entities:  

Keywords:  Antipsychotics; adverse effects; agranulocytosis; akathisia; dystonias; impulse control disorders; metabolic effects; neuroleptic malignant syndrome; orthostatic hypotension; parkinsonism; schizophrenia; sedation; sexual function; sialorrhea; tardive dyskinesia

Year:  2018        PMID: 30192094      PMCID: PMC6127750          DOI: 10.1002/wps.20567

Source DB:  PubMed          Journal:  World Psychiatry        ISSN: 1723-8617            Impact factor:   49.548


  250 in total

1.  Clozapine and sialorrhea: update.

Authors:  P Tessier; C Antonello
Journal:  J Psychiatry Neurosci       Date:  2001-05       Impact factor: 6.186

Review 2.  Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia.

Authors:  Samer Alabed; Youssef Latifeh; Husam Aldeen Mohammad; Abdullah Rifai
Journal:  Cochrane Database Syst Rev       Date:  2011-04-13

3.  BDNF Val66Met polymorphism and antipsychotic-induced tardive dyskinesia occurrence and severity: a meta-analysis.

Authors:  Itaru Miura; Jian-Ping Zhang; Masahiro Nitta; Todd Lencz; John M Kane; Anil K Malhotra; Hirooki Yabe; Christoph U Correll
Journal:  Schizophr Res       Date:  2014-01-07       Impact factor: 4.939

Review 4.  Neuroleptic-induced extrapyramidal reactions: classification, description, and diagnosis.

Authors:  D Tarsy
Journal:  Clin Neuropharmacol       Date:  1983       Impact factor: 1.592

5.  Propranolol in the treatment of neuroleptic-induced akathisia (NIA) in schizophrenics: a double-blind, placebo-controlled study.

Authors:  M S Kramer; R A Gorkin; C DiJohnson; P Sheves
Journal:  Biol Psychiatry       Date:  1988-11       Impact factor: 13.382

6.  Sulpiride addition for the treatment of clozapine-induced hypersalivation: preliminary study.

Authors:  Anatoly Kreinin; Svetlana Epshtein; Ayala Sheinkman; Emanuel Tell
Journal:  Isr J Psychiatry Relat Sci       Date:  2005       Impact factor: 0.481

7.  Ethopropazine and benztropine in neuroleptic-induced parkinsonism.

Authors:  G Chouinard; L Annable; A Ross-Chouinard; M L Kropsky
Journal:  J Clin Psychiatry       Date:  1979-03       Impact factor: 4.384

Review 8.  Antipsychotic-related QTc prolongation, torsade de pointes and sudden death.

Authors:  Peter M Haddad; Ian M Anderson
Journal:  Drugs       Date:  2002       Impact factor: 9.546

9.  The Antipsychotics and Sexual Functioning Questionnaire (ASFQ): preliminary evidence for reliability and validity.

Authors:  Marrit K de Boer; Stynke Castelein; Johan Bous; Edwin R van den Heuvel; Durk Wiersma; Robert A Schoevers; Henderikus Knegtering
Journal:  Schizophr Res       Date:  2013-09-21       Impact factor: 4.939

Review 10.  Modafinil as an adjunctive treatment of sedation, negative symptoms, and cognition in schizophrenia: a critical review.

Authors:  Carlos Saavedra-Velez; Anna Yusim; Deepti Anbarasan; Jean-Pierre Lindenmayer
Journal:  J Clin Psychiatry       Date:  2008-11-18       Impact factor: 4.384

View more
  56 in total

1.  The prevalence and independent influencing factors of obesity and underweight in patients with schizophrenia: a multicentre cross-sectional study.

Authors:  Juan Wang; Yulong Zhang; Yating Yang; Zhiwei Liu; Lei Xia; Wenzheng Li; Zhongxiang Li; Xinhui Xie; Wenfeng Deng; Kai Zhang; Huanzhong Liu
Journal:  Eat Weight Disord       Date:  2020-06-17       Impact factor: 4.652

2.  Management of sexual adverse effects induced by atypical antipsychotic medication

Authors:  Laura Downing; David D. Kim; Ric M. ` Procyshyn; Philip Tibbo
Journal:  J Psychiatry Neurosci       Date:  2019-07-01       Impact factor: 6.186

3. 

Authors:  Japheth Bool; Alex Crawley; Annabelle Wanson; Breanna Davis; Katelyn Halpape
Journal:  Can Fam Physician       Date:  2021-05       Impact factor: 3.275

4.  Pharmacotherapy management of schizophrenia for family physicians.

Authors:  Japheth Bool; Alex Crawley; Annabelle Wanson; Breanna Davis; Katelyn Halpape
Journal:  Can Fam Physician       Date:  2021-05       Impact factor: 3.275

Review 5.  Transdermal Delivery of Antipsychotics: Rationale and Current Status.

Authors:  Angela Abruzzo; Teresa Cerchiara; Barbara Luppi; Federica Bigucci
Journal:  CNS Drugs       Date:  2019-09       Impact factor: 5.749

6.  Beneficial Effects of Acupuncture as a Complementary Treatment for Patients Receiving Paroxetine For Major Depressive Disorder: A Meta-Analysis.

Authors:  Minh Duc Nguyen; Quoc Vinh Nguyen; Cay Doan Ha; Thanh Van Tran; Linh Vu Phuong Dang
Journal:  Med Acupunct       Date:  2021-12-16

7.  Safety of 80 antidepressants, antipsychotics, anti-attention-deficit/hyperactivity medications and mood stabilizers in children and adolescents with psychiatric disorders: a large scale systematic meta-review of 78 adverse effects.

Authors:  Marco Solmi; Michele Fornaro; Edoardo G Ostinelli; Caroline Zangani; Giovanni Croatto; Francesco Monaco; Damir Krinitski; Paolo Fusar-Poli; Christoph U Correll
Journal:  World Psychiatry       Date:  2020-06       Impact factor: 49.548

8.  Autoimmune Encephalitis in a Girl With Psychiatric Manifestations.

Authors:  Anum Haider; Areeba Rehman; Summaiyya Waseem; Saad Khalid
Journal:  Cureus       Date:  2021-04-16

9.  Effect of antipsychotic drugs and orthostatic hypotension on the risk of falling in schizophrenic patients.

Authors:  Ferinauli Ferinauli; Sari Narulita; Yoanita Hijriyati
Journal:  J Public Health Res       Date:  2021-04-14

10.  Fidelity of Delivery and Contextual Factors Influencing Children's Level of Engagement: Process Evaluation of the Online Remote Behavioral Intervention for Tics Trial.

Authors:  Kareem Khan; Chris Hollis; Charlotte L Hall; Elizabeth Murray; E Bethan Davies; Per Andrén; David Mataix-Cols; Tara Murphy; Cris Glazebrook
Journal:  J Med Internet Res       Date:  2021-06-21       Impact factor: 5.428

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.